Head and Neck Research Studies
HIGH-RISK SQUAMOUS CELL
HN001: Randomized Phase II and Phase III Studies of Individualized for Nasopharyngeal Carcinoma Base on Biomarker Epstein Barr Virus (EBV) Deoxyriboncleic Acid (DNA).
HN003: A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC).
R0920: Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head and Neck Cancer.
HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin.
SALIVARY GLAND TUMORS
R1008: Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors.
A091404: A Phase II Study of Enzalutamide for Patients with Androgen Receptor Positive Salivary Cancers.